Overview
Porter Neuroscience Building (35A)
Room 620/630
The purpose of the symposium is to bring together and inform the academic and community hospital clinicians about the latest clinical and translational research in myelodysplastic syndromes and secondary AML currently taking place at the NCI CCR and the NIH intramural research programs. The agenda will cover following objectives:
- Understanding the biology of MDS and update on the currently emerging therapies for this disease
- Update the attendees with the preclinical and translational research currently ongoing at the NIH intramural programs
- Familiarize attendees with clinical trials available or being planned at the NCI CCR and the NIH Clinical Center for refractory or relapsed MDS or AML
The symposium will include speakers from the NIH intramural research programs and a special keynote guest speaker
Overall Goal
Review most recent advancement of biology and therapeutics for MDS and secondary AML. Provide information on MDS clinical trials currently available or planned at the NCI Phase 1 Developmental Therapeutics Clinic and the CCR. Build a strong patient referral base collaboration between the extramural community oncologists and academia oncologists/hematologists to develop future cures and novel treatments for these diseases.
Organizing Committee
Steven Pavletic, M.D., Head, Graft-versus-Host and Late Effects Section, Immune Deficiency and Cell Therapy Program, CCR, NCI
Naoko Takebe, M.D., Ph.D., Associate Chief Developmental Therapeutics Clinic, Early Clinical Trials Development Program, DCTD, NCI
Sabrina Khan, M.D., M.Ph., Clinical Fellow, Developmental Therapeutics Clinic, DCTD, NCI
In collaboration with the NIH Myeloid Malignancy Special Interest Group